These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 12645827

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM.
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B.
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 8. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M, Briggs AH, Grossman RF, Rance L.
    Pharmacoeconomics; 2005 Apr; 23(6):619-37. PubMed ID: 15960557
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
    Lundbäck B, Jenkins C, Price MJ, Thwaites RM.
    Respir Med; 2000 Jul; 94(7):724-32. PubMed ID: 10926346
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease.
    van der Palen J, Monninkhof E, van der Valk P, Sullivan SD, Veenstra DL.
    Thorax; 2006 Jan; 61(1):29-33. PubMed ID: 16244087
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF.
    Pharmacoeconomics; 2006 Jan; 24(7):695-708. PubMed ID: 16802845
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P.
    Pharmacoeconomics; 2004 Jan; 22(12):815-25. PubMed ID: 15294013
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
    Ismaila AS, Birk R, Shah D, Zhang S, Brealey N, Risebrough NA, Tabberer M, Zhu CQ, Lipson DA.
    Adv Ther; 2017 Sep; 34(9):2163-2172. PubMed ID: 28875459
    [Abstract] [Full Text] [Related]

  • 16. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study.
    van Grunsven P, Schermer T, Akkermans R, Albers M, van den Boom G, van Schayck O, van Herwaarden C, van Weel C.
    Respir Med; 2003 Dec; 97(12):1303-12. PubMed ID: 14682412
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.
    van den Boom G, Rutten-van Mölken MP, Molema J, Tirimanna PR, van Weel C, van Schayck CP.
    Am J Respir Crit Care Med; 2001 Dec 01; 164(11):2057-66. PubMed ID: 11739135
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.